For a patient with HER2+ breast cancer with progressive but asymptomatic disease in the brain, would you hold off on WBRT to do a trial of tucatinib, or proceed with WBRT then tucatinib?

Assuming the patient is not a candidate for SRS

Answer from: Radiation Oncologist at Community Practice

The trial allowed both treated and untreated brain mets, and showed response rate and improved survival. If the patient is not a candidate for SRS, it’s reasonable to watch brain lesions with serial MRIs.

Comments

Medical Oncologist at Saint Elizabeth Regional Medical Center
How would you obtain tucatinib, I am assuming thro...

Please select the option that best describes you:

For a patient with HER2+ breast cancer with progressive but asymptomatic disease in the brain, would you hold off on WBRT to do a trial of tucatinib, or proceed with WBRT then tucatinib?

Related Questions